Beam Therapeutics Inc. Stock Analysis & AI Score
Beam Therapeutics Inc. (BEAM) has an ST Score of 64.0 (B), driven by its Sentiment (A+) and held back by its Growth (C-). Analysts rate it Buy with a $59.50 price target (+141.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Beam Therapeutics Inc. (BEAM) has an ST Score of 64.0 (B), driven by its Sentiment (A+) and held back by its Growth (C-). Analysts rate it Buy with a $59.50 price target (+141.3% upside).
- Strongest
- SentimentA+
- Weakest
- GrowthC-
All factor grades
- SentimentA+
- ProfitabilityA
- ForecastA
- ValuationB
- Financial StrengthB
- MomentumC+
- GrowthC-
- Piotroski3/9
Contact
BEAM stock: frequently asked questions
What is BEAM's ST Score?
Beam Therapeutics Inc. (BEAM) has an ST Score of 64.0 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BEAM a buy, hold, or sell?
Analysts rate BEAM a Buy, with a price target of $59.50 (+141.3% vs the current price). Our ST Score grades it B (64.0/100). The ST Score is a data-driven signal, not a recommendation.
What are BEAM's factor grades?
Valuation B, Profitability A, Financial Strength B, Momentum C+, Growth C-, Forecast A, Sentiment A+.
What is BEAM's valuation grade?
Beam Therapeutics Inc. (BEAM) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BEAM's growth grade?
Beam Therapeutics Inc. (BEAM) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BEAM's profitability grade?
Beam Therapeutics Inc. (BEAM) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BEAM's financial strength grade?
Beam Therapeutics Inc. (BEAM) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BEAM?
The average analyst price target for Beam Therapeutics Inc. (BEAM) is $59.50 from 27 analysts, which is +141.3% versus the recent price of $24.66.
What is BEAM's Piotroski score?
Beam Therapeutics Inc. (BEAM) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.